[go: up one dir, main page]

WO2002030959A3 - Peptides derives de smac (diablo) et procedes d'utilisation de ceux-ci - Google Patents

Peptides derives de smac (diablo) et procedes d'utilisation de ceux-ci Download PDF

Info

Publication number
WO2002030959A3
WO2002030959A3 PCT/US2001/032121 US0132121W WO0230959A3 WO 2002030959 A3 WO2002030959 A3 WO 2002030959A3 US 0132121 W US0132121 W US 0132121W WO 0230959 A3 WO0230959 A3 WO 0230959A3
Authority
WO
WIPO (PCT)
Prior art keywords
diablo
smac
peptides derived
methods
use therefor
Prior art date
Application number
PCT/US2001/032121
Other languages
English (en)
Other versions
WO2002030959A2 (fr
Inventor
Stephen W Fesik
Robert P Meadows
Stephen P Betz
Zhihong Liu
Edward T Olejniczak
Chaohong Sun
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of WO2002030959A2 publication Critical patent/WO2002030959A2/fr
Publication of WO2002030959A3 publication Critical patent/WO2002030959A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des peptides dérivés de la protéine humaine smac (DIABLO) de type sauvage qui se lie avec un membre de la famille des IAP (inhibitor of apoptosis proteins : protéines inhibant l'apoptose). Ces peptides peuvent être utilisés dans un procédé permettant l'identification de substances candidates induisant ou favorisant l'apoptose dans les cellules..
PCT/US2001/032121 2000-10-13 2001-10-12 Peptides derives de smac (diablo) et procedes d'utilisation de ceux-ci WO2002030959A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68754900A 2000-10-13 2000-10-13
US09/687,549 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002030959A2 WO2002030959A2 (fr) 2002-04-18
WO2002030959A3 true WO2002030959A3 (fr) 2002-09-26

Family

ID=24760847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032121 WO2002030959A2 (fr) 2000-10-13 2001-10-12 Peptides derives de smac (diablo) et procedes d'utilisation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2002030959A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
US9040706B2 (en) 2004-12-20 2015-05-26 Genentech, Inc. Pyrrolidine inhibitors of IAP

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026775A2 (fr) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions et methodes de regulation de l'apoptose
AU2003249920A1 (en) * 2002-07-02 2004-01-23 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2005084317A2 (fr) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Petites molecules dimeres inductrices d'apoptose
JP5122275B2 (ja) 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
KR100984459B1 (ko) 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
EP1773766B1 (fr) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Composes de liaison aux proteines iap
EP1851200B1 (fr) 2005-02-25 2014-01-15 Tetralogic Pharmaceuticals Corporation Inhibiteurs iap dimeriques
WO2006122408A1 (fr) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Composes liants de domaine bir
EP1951698A4 (fr) 2005-10-25 2010-04-28 Aegera Therapeutics Inc Composés de liaison au domaine iap bir
EP1973899A4 (fr) 2005-12-19 2010-10-20 Genentech Inc Inhibiteurs iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
WO2008014252A2 (fr) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Inhibiteurs des iap
KR20090041391A (ko) 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
US8063218B2 (en) 2006-12-19 2011-11-22 Genentech, Inc. Imidazopyridine inhibitors of IAP
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
CN110713546B (zh) * 2019-10-31 2021-04-20 中国医科大学附属第一医院 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021015A2 (fr) * 1997-10-21 1999-04-29 Cranfield University Ligands d'affinite, leur production, et leur utilisation
WO2002016418A2 (fr) * 2000-08-24 2002-02-28 Thomas Jefferson University Peptide ou polypeptide capable de liaison avec l'inhibiteur de la proteine de l'apoptose
WO2002016402A2 (fr) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Composes apoptotiques
WO2002026775A2 (fr) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions et methodes de regulation de l'apoptose

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021015A2 (fr) * 1997-10-21 1999-04-29 Cranfield University Ligands d'affinite, leur production, et leur utilisation
WO2002016402A2 (fr) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Composes apoptotiques
WO2002016418A2 (fr) * 2000-08-24 2002-02-28 Thomas Jefferson University Peptide ou polypeptide capable de liaison avec l'inhibiteur de la proteine de l'apoptose
WO2002026775A2 (fr) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions et methodes de regulation de l'apoptose

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAI JIJIE ET AL: "STRUCTURAL AND BIOCHEMICAL BASIS OF APOPTOTIC ACTIVATION BY SMAC/DIABLO.", NATURE (LONDON), vol. 406, no. 6798, 2000, pages 855 - 862, XP002200489, ISSN: 0028-0836 *
DU CHUNYING ET AL: "Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 102, no. 1, 7 July 2000 (2000-07-07), pages 33 - 42, XP002175396, ISSN: 0092-8674 *
VERHAGEN ANNE M ET AL: "IDENTIFICATION OF DIABLO, A MAMMALIAN PROTEIN THAT PROMOTES APOPTOSIS BY BINDING TO AND ANTAGONIZING IAP PROTEINS", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 102, 7 July 2000 (2000-07-07), pages 43 - 53, XP002175397, ISSN: 0092-8674 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040706B2 (en) 2004-12-20 2015-05-26 Genentech, Inc. Pyrrolidine inhibitors of IAP
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP

Also Published As

Publication number Publication date
WO2002030959A2 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2002030959A3 (fr) Peptides derives de smac (diablo) et procedes d'utilisation de ceux-ci
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP2141243A3 (fr) Supports de protéine pour mimer des anticorps et d'autres protéines de liaison
WO2003045310A8 (fr) Dosage biologique numerique
AU2001286730A1 (en) An iap binding peptide or polypeptide and methods of using the same
AU2003253784A1 (en) Peptides from the e2, e6 and e7 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other cancers
WO2002020568A3 (fr) Peptides mutants derives de bad et leur utilisation pour identifier des substances se liant a un element de la famille de proteines bcl-2
AU2002321931A1 (en) Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2002008767A3 (fr) Nouveaux procedes et trousses de sequençage de polypeptides
EP1136547A3 (fr) Polypeptides Adamts, acides nucléiques codant pour ces polypeptides et leurs utilisations
AU2002214542A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2001045738A3 (fr) Utilisation de proteines de choc thermique
AU2002213450A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2001250999A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002340881A1 (en) Concentration of protein and/or peptides samples
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2002010417A3 (fr) Procedes et compositions pour la construction et l'utilisation de virus a enveloppe comme particules de presentation
WO2002094777A3 (fr) Procede pour detecter la methyltransferase d'arginine et utilisations du procede
AU2002365084A1 (en) Method and reagent for the detection of proteins and peptides
AU1657501A (en) Determining the functions and interactions of proteins by comparative analysis
WO2004094989A3 (fr) Methodes d'analyse de proteines de cellule hote
EP1134286A3 (fr) Adamts polypeptides, acides nucléiques les codant et leurs applications
WO2003100075A3 (fr) Acides nucleiques et proteines bsnd
AU2001288363A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2000057184A3 (fr) Tests, methodes et moyens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP